ASN and the U.S. Department of Health and Human Services (HHS) have sent a clear signal in their desire to have new therapies in the kidney space through the signing of a Memorandum of Understanding establishing the Kidney Innovation Accelerator (KidneyX), a collaborative environment in which a community of researchers, innovators, and investors can participate. This new public-private partnership aims to prevent future kidney disease, while improving the lives of the 850,000,000 people worldwide who are currently affected by accelerating innovation in the prevention, diagnosis, and treatment of kidney diseases.
ASN and the U.S. Department of Health and Human Services (HHS) have sent a clear signal in their desire to have new therapies in the kidney space through the signing of a Memorandum of Understanding establishing the Kidney Innovation Accelerator (KidneyX), a collaborative environment in which a community of researchers, innovators, and investors can participate. This new public-private partnership aims to prevent future kidney disease, while improving the lives of the 850,000,000 people worldwide who are currently affected by accelerating innovation in the prevention, diagnosis, and treatment of kidney diseases.
KidneyX will accelerate the commercialization of more products to benefit people with and at risk for kidney diseases through prize funding awarded to promising participants. Using a three-pronged approach, KidneyX will address the barriers innovators commonly identify as they look to bring new drugs and technologies in kidney care to market, bridging the gap between research and market-ready products.
First, the Accelerator will provide merit-based, non-dilutive funding to promising innovators selected through a prize competition. KidneyX’s first round of prize funding will focus on accelerating the commercialization of next-generation dialysis products before expanding to other categories of disruptive technologies in kidney care.
Second, KidneyX will help clarify the path toward commercialization by encouraging better coordination across HHS with the National Institutes of Health (NIH), Food and Drug Administration (FDA), and Centers for Medicare & Medicaid Services (CMS).
The third prong of KidneyX’s approach to accelerate innovation in kidney care is to create a sense of urgency to develop new therapies, much like the sense of urgency associated with other areas of healthcare. An important part of this effort will be the opening pathways of collaboration among science, engineering, finance, and other disciplines.
The Kidney Health Initiative’s (KHI) Development of a Roadmap for Innovation in Renal Replacement Therapy (RRT) project will serve as a resource for KidneyX participants. The KHI project aims to describe scientific, technical, and regulatory milestones needed to achieve the goal of creating a bioartificial or bioengineered alternative to dialysis as RRT.
The first round of prize funding will begin accepting applications in 2018. Individuals that are interested in learning more about KidneyX are encouraged to visit www.kidneyx.org , and join our mailing list.
© 2021 American Society of Nephrology | All Rights Reserved
Powered by: PubFactory